肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

耐药性晚期癌症如何治疗？靶向耐药途径IRS1/2和STAT3的NT219即将进行I/II期临床试验

2020-05-24 Allan MedSci原创

STAT3NT219耐药途径IRS1/2
关注

Kitov是一家临床阶段的生物技术公司，致力于克服肿瘤的免疫逃逸和耐药性。

Kitov是一家临床阶段的生物技术公司，致力于克服肿瘤的免疫逃逸和耐药性，Kitov近日宣布，美国FDA已接受其研究性药物（IND）申请，允许开展NT219治疗耐药性晚期癌症的I/II期临床试验。NT219是一种针对晚期癌症耐药性的新型药物，是靶向耐药途径IRS1/2和STAT3的小分子。这项研究将评估NT219作为单药疗法或与利妥昔单抗（抗EGFR单克隆抗体）联合治疗复发或转移性实体瘤（包括头颈癌和鳞状细胞癌）的有效性和安全性。

Kitov首席医学官Bertrand Liang博士说：“基于NT219的临床前数据，我们认为该候选药物有望成为治疗多种耐药性癌症有效疗法”。开放标签的I期临床试验的主要目标是评估安全性和药代动力学，确定在II期临床试验中合适的剂量以及确定NT219的初步疗效。

 

原始出处：

https://www.firstwordpharma.com/node/1726663?tsid=4

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1653033, encodeId=c1a716530331a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Oct 03 21:42:47 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088806, encodeId=93972088806ec, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Sep 10 08:42:47 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931513, encodeId=05e7193151321, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Jan 10 10:42:47 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700259, encodeId=70861e00259ae, content=<a href='/topic/show?id=41291311387' target=_blank style='color:#2F92EE;'>#NT219#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13113, encryptionId=41291311387, topicName=NT219)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=643130016968, createdName=俅侠, createdTime=Wed Jul 22 07:42:47 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348976, encodeId=cb4e13489e606, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Tue May 26 09:42:47 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524818, encodeId=e2821524818aa, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue May 26 09:42:47 CST 2020, time=2020-05-26, status=1, ipAttribution=)]
    2020-10-03 医生2402

    #I期临床#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1653033, encodeId=c1a716530331a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Oct 03 21:42:47 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088806, encodeId=93972088806ec, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Sep 10 08:42:47 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931513, encodeId=05e7193151321, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Jan 10 10:42:47 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700259, encodeId=70861e00259ae, content=<a href='/topic/show?id=41291311387' target=_blank style='color:#2F92EE;'>#NT219#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13113, encryptionId=41291311387, topicName=NT219)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=643130016968, createdName=俅侠, createdTime=Wed Jul 22 07:42:47 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348976, encodeId=cb4e13489e606, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Tue May 26 09:42:47 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524818, encodeId=e2821524818aa, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue May 26 09:42:47 CST 2020, time=2020-05-26, status=1, ipAttribution=)]
    2020-09-10 839640778

    #I期临床试验#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1653033, encodeId=c1a716530331a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Oct 03 21:42:47 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088806, encodeId=93972088806ec, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Sep 10 08:42:47 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931513, encodeId=05e7193151321, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Jan 10 10:42:47 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700259, encodeId=70861e00259ae, content=<a href='/topic/show?id=41291311387' target=_blank style='color:#2F92EE;'>#NT219#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13113, encryptionId=41291311387, topicName=NT219)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=643130016968, createdName=俅侠, createdTime=Wed Jul 22 07:42:47 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348976, encodeId=cb4e13489e606, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Tue May 26 09:42:47 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524818, encodeId=e2821524818aa, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue May 26 09:42:47 CST 2020, time=2020-05-26, status=1, ipAttribution=)]
    2021-01-10 kksonne

    #II期临床试验#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1653033, encodeId=c1a716530331a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Oct 03 21:42:47 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088806, encodeId=93972088806ec, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Sep 10 08:42:47 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931513, encodeId=05e7193151321, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Jan 10 10:42:47 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700259, encodeId=70861e00259ae, content=<a href='/topic/show?id=41291311387' target=_blank style='color:#2F92EE;'>#NT219#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13113, encryptionId=41291311387, topicName=NT219)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=643130016968, createdName=俅侠, createdTime=Wed Jul 22 07:42:47 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348976, encodeId=cb4e13489e606, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Tue May 26 09:42:47 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524818, encodeId=e2821524818aa, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue May 26 09:42:47 CST 2020, time=2020-05-26, status=1, ipAttribution=)]
    2020-07-22 俅侠

    #NT219#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1653033, encodeId=c1a716530331a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Oct 03 21:42:47 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088806, encodeId=93972088806ec, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Sep 10 08:42:47 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931513, encodeId=05e7193151321, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Jan 10 10:42:47 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700259, encodeId=70861e00259ae, content=<a href='/topic/show?id=41291311387' target=_blank style='color:#2F92EE;'>#NT219#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13113, encryptionId=41291311387, topicName=NT219)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=643130016968, createdName=俅侠, createdTime=Wed Jul 22 07:42:47 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348976, encodeId=cb4e13489e606, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Tue May 26 09:42:47 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524818, encodeId=e2821524818aa, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue May 26 09:42:47 CST 2020, time=2020-05-26, status=1, ipAttribution=)]
    2020-05-26 李研东

    #STAT3#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1653033, encodeId=c1a716530331a, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sat Oct 03 21:42:47 CST 2020, time=2020-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088806, encodeId=93972088806ec, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Thu Sep 10 08:42:47 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1931513, encodeId=05e7193151321, content=<a href='/topic/show?id=a3d89601f2' target=_blank style='color:#2F92EE;'>#II期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9601, encryptionId=a3d89601f2, topicName=II期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Sun Jan 10 10:42:47 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1700259, encodeId=70861e00259ae, content=<a href='/topic/show?id=41291311387' target=_blank style='color:#2F92EE;'>#NT219#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13113, encryptionId=41291311387, topicName=NT219)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=643130016968, createdName=俅侠, createdTime=Wed Jul 22 07:42:47 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1348976, encodeId=cb4e13489e606, content=<a href='/topic/show?id=684f16e52c8' target=_blank style='color:#2F92EE;'>#STAT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16752, encryptionId=684f16e52c8, topicName=STAT3)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Tue May 26 09:42:47 CST 2020, time=2020-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524818, encodeId=e2821524818aa, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Tue May 26 09:42:47 CST 2020, time=2020-05-26, status=1, ipAttribution=)]
    2020-05-26 guihongzh

    #II期临床#

    0

相关资讯

Blood：全身炎症反应过程中诱导吞噬细胞耐受的信号机制

吞噬细胞对外源性和内源性刺激的炎症反应受到严格的调控。这种调节在全身炎症反应综合征(SIRS)中具有重要作用。在SIRS中，吞噬细胞最初会发生一种超炎症反应，随后转为一种次级的低反应状态，即所谓的耐受。这种低反应性可由Toll样受体4 (TLR4)的内毒素刺激引起，从而在以后的再刺激条件下改善反应。这种炎症反应模式的调整被称为固有免疫记忆。

Blood：在自然杀伤T细胞淋巴瘤中，STAT3信号通路激活可上调PD-L1的表达！

中心点：在PTCT和NKTL中，JAK/STAT信号通路常发生改变，其中STAT3和TP53是最常见的突变基因。在NKTL中，STAT3激活可促进PD-L1过表达，为STAT3抑制剂与免疫检查点抑制剂结合提供理论基础。摘要：成熟T细胞淋巴瘤，包括外周T细胞淋巴瘤（PTCL）和淋巴结外NK/T细胞淋巴瘤（NKTL），代表了一组异质性的非霍奇金淋巴瘤，治疗方案有限、预后差。为明确JAK/STAT信号通

FDA批准STAT3抑制剂WP1066治疗小儿脑癌试验的IND

WPD是一家临床阶段制药公司，今日宣布，美国FDA批准了STAT3抑制剂WP1066治疗小儿复发性或难治性恶性脑肿瘤的研究性新药（IND）申请，以开展I期临床试验，该试验将在亚特兰大儿童保健中心进行。

Blood：在弥漫性大B细胞淋巴瘤中，B细胞受体介导的NFATc1激活可诱导IL-10/STAT3/PD-L1信号

中心点：在DLBCL细胞中，B细胞受体（BCR）介导的NFATc1激活刺激免疫抑制IL-10/STAT3/PD-L1信号通路。用BTK的小分子抑制剂封闭BCR介导的NFATc1激活，可下调DLBCL细胞的IL-10/STAT3/PD-L1信号。摘要：目前对PD-L1在B细胞淋巴瘤细胞中的表达及调控的了解有限。研究PD-L1在B细胞淋巴瘤中的表达调控机制或许可鉴别出能预测采用用抗PD-1/PD-L1

Blood：Cirmtuzumab的抗慢性淋巴细胞白血病机制！

将Nurse样细胞（NLC）与慢性淋巴细胞白血病（CLL）细胞共培养，可诱导白血病细胞的STAT3磷酸化（pSTAT3），该过程可被抗Wnt5a抗体或抗ROR1 mAb cirmtuzumab阻断。研究表明Wnt5a可在30min内诱导NF-κB活化，但需要3个多小时来诱导pSTAT3。

Cell Death Dis：BECN1在结直肠癌转移中的作用及潜在机制

细胞自噬是一种涉及捕获、降解和回收溶酶体中的细胞内蛋白和细胞器的促生存反应。癌症中细胞自噬作用的增强能够促进肿瘤微环境中癌细胞的存活率，促进癌细胞的生长和侵袭能力。

拓展阅读

Cancer Discov：基于AI模型预测肿瘤何时会对化疗产生耐药性

文章报道了如何利用机器学习算法来解决癌症研究面临的最大挑战之一：预测肿瘤何时会对化疗产生耐药性。

Pan Afr Med J ：2017-2018年莫桑比克艾滋病毒耐药性监测系统评估

2019年，全球约67%的艾滋病毒感染者接受了抗逆转录病毒治疗，其中26%开始治疗的人感染了对一线药物(如依法韦仑)耐药的病毒。

Gastroenterology：釜底抽薪：改变饮食让癌细胞“挨饿”，克服癌症治疗耐药性

此前有研究显示，mTORC1在结直肠癌中高度活跃，但科学家们对于结肠癌是否劫持了营养传感通路来激活主调控因子仍未有结论。

研究发现：一种免疫蛋白有望应对抗生素耐药性

这种蛋白质可以像“斧子劈木头”一样，将细菌破坏掉，致其死亡。

掌握这几点，难治性痤疮不再犯难

难治性痤疮的病因分析，和应对措施

Br J Dermatol ：对多种生物疗法耐药的银屑病患者：难治人群的特征和定义

在过去十与年里针对中重度银屑病的生物疗法的大量涌现，很多患者得到良好的治疗，但也有一些患者对生物制剂产生耐药性，该文对这些难治人群的特征和定义进行了研究。